Shifts in body mass index category with tirzepatide and associated changes in cardiometabolic risk factors in people with obesity: a post hoc analysis from the SURMOUNT-1 and SURMOUNT-4 trials

American Journal of Preventive Cardiology 2026 Open access

Read full text
Authors: Naveed Sattar, Clare J. Lee, Reshmi Srinath, Philip R. Schauer, Hui Wang, Beverly Falcon, XUANYAO HE, Adam Stefanski, ARIAN W. PLAT
DOI: 10.1016/j.ajpc.2026.101454
Cited by: 2
References: 23

Abstract

Obesity is a chronic disease that results in increased morbidity and mortality if left untreated. Tirzepatide is a glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist approved in the United States for the treatment of type 2 diabetes, obesity, and obstructive sleep apnea. These post hoc analyses assessed the cardiometabolic risk factors of participants with obesity or overweight treated with tirzepatide who shifted to a lower body mass index (BMI) category. Shifts in BMI categories (

Fields of Study & Subjects

Blood Pressure and Hypertension Studies Cardiovascular Function and Risk Factors Physical Activity and Health

Publication details

Journal / source
American Journal of Preventive Cardiology
Publisher
Elsevier BV
Volume
26
Pages
101454–101454
Publication date
25 February 2026
Language
EN